1. Home
  2. NVAX vs AGIO Comparison

NVAX vs AGIO Comparison

Compare NVAX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Novavax Inc.

NVAX

Novavax Inc.

SELL

Current Price

$8.05

Market Cap

2.1B

Sector

Health Care

ML Signal

SELL

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

SELL

Current Price

$30.16

Market Cap

2.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NVAX
AGIO
Founded
1987
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.2B
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
NVAX
AGIO
Price
$8.05
$30.16
Analyst Decision
Buy
Buy
Analyst Count
9
10
Target Price
$14.11
★ $46.11
AVG Volume (30 Days)
★ 5.8M
1.1M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 309.76
N/A
EPS
★ N/A
N/A
Revenue
★ $1,123,479,000.00
$43,011,000.00
Revenue This Year
N/A
$227.92
Revenue Next Year
N/A
$96.10
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 64.69
N/A
52 Week Low
$6.20
$22.24
52 Week High
$13.39
$46.00

Technical Indicators

Market Signals
Indicator
NVAX
AGIO
Relative Strength Index (RSI) 34.94 42.85
Support Level $7.48 $26.57
Resistance Level $10.64 $35.77
Average True Range (ATR) 0.71 1.83
MACD -0.23 -0.19
Stochastic Oscillator 1.09 25.75

Price Performance

Historical Comparison
NVAX
AGIO

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: